Clinical trials
Autoimmune Liver Disease clinical trials
Below are recruiting autoimmune liver disease clinical trials, each written for real people, not researchers. We’re tracking 180 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06868992Recruiting
Study of MASH and cell changes in weight-loss surgery
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
Lyon, FranceAges 18–99 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Redwood City, CaliforniaAges 18–70 - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07143617Recruiting
Safety study of STR-P004 for lupus and inflammatory muscle disease
This trial tests the safety of a new treatment called STR-P004 for people with systemic lupus erythematosus (SLE) or certain inflammatory muscle diseases that have not improved with standard therapies. It may be an option if your condition is hard to control.
BeijingAges 18 years+ - NCT07143968RecruitingPhase 2
Resmetirom for people with MASLD and HIV
This study tests if resmetirom can help people who have both HIV and a liver condition called MASLD (fat buildup in the liver not caused by alcohol). You may qualify if your liver has a certain amount of fat and stiffness, and your HIV is well controlled with stable medication.
Birmingham, AlabamaAges 18 years+ - NCT07193810RecruitingEarly Phase 1
CC312 for autoimmune diseases that returned or didn't respond
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Deyang, SichuanAges 18–65 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07237750Recruiting
Weight loss trial: endoscopy procedure vs lifestyle changes
This study compares a new endoscopic procedure (a stomach tightening treatment done through a tube in your mouth) with a structured diet and exercise program to help with weight loss. It is for Asian adults who have tried and failed to lose weight before.
Beijing, Beijing MunicipalityAges 18–65 - NCT00345930Recruiting
Study of liver injury after medicines or supplements
This study looks at people (including children over age 2) who develop liver injury that may be caused by a drug or a complementary/alternative medicine (CAM) product. It helps doctors better understand what causes the injury and how to evaluate it.
Los Angeles, CaliforniaAges 2 years+ - NCT00575133Recruiting
Study of people with fatty liver disease
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
Zurich, Canton of ZurichAges 18 years+ - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75 - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07662902Enrolling by invitation
Gut Barrier Study in Ulcerative Colitis Remission
This study looks at gut barrier function in people with ulcerative colitis who are in remission. It uses a non-invasive liver test to check for subtle changes in the body.
ZagrebAges 18–70 - NCT05859997Enrolling by invitation
CAR-T cell therapy for active autoimmune disease flare-ups
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06647069RecruitingPhase 1
Testing a new drug for lupus and rheumatoid arthritis
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Brisbane, QueenslandAges 18–75 - NCT07473154RecruitingPhase 1/Phase 2
Calming an overactive immune system with special cells
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
BirminghamAges 18 years+
Hear when a new Autoimmune Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune liver disease?
- Yes. Clin2 currently lists 180 recruiting autoimmune liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.